Parkinson's disease severity and use of dopaminergic medications

Affiliations

¹ Department of Neurology, Vanderbilt University, 1161 21st Ave South, A-0118, Nashville, TN 37232, USA. Electronic address: john.y.fang@vanderbilt.edu.
² UTHealth, The University of Texas School of Public Health, Austin Regional Campus, University of Texas Administration Building (UTA), 1616 Guadalupe Street, Suite 6.300, Austin, TX 78701, USA.
³ Department of Neurology, University of California at San Francisco, 400 Parnassus Ave, Box 0348, San Francisco, CA 94143, USA.
⁴ Department of Neurology, University of Colorado School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA.
⁵ Department of Neurology, School of Medicine, University of California at San Francisco, 505 Parnassus Ave, Box 0114, San Francisco, CA 94143-0114, USA.
⁶ Department of Neurological Sciences, University of Vermont College of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA.
⁷ Movement and Cognitive Disorders Center, Department of Neurology, Medical College of Georgia, Georgia Regents University, 1429 Harper Street, HF-1154, Augusta, GA 30912, USA.
⁸ Barrow Neurological Institute, 240 W Thomas Road, Suite 301, Phoenix, AZ 85013, USA.
⁹ Department of Neurology, University of Alabama at Birmingham and The Birmingham VA Medical Center, 1720 2nd Avenue South, Birmingham, AL 35294, USA.
¹⁰ Department of Neurology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA; Department of Ophthalmology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA.
¹¹ Department of Neurology, LSU Health Sciences Center in Shreveport, 1501 King's Highway, Shreveport, LA 71130, USA.
¹² Department of Neurology, Michigan State University, 804 Service Rd, Room A217, USA.

PMID: 25541182
PMCID: PMC4340731
DOI: 10.1016/j.parkreldis.2014.10.016

Parkinson's disease severity and use of dopaminergic medications

John Y Fang et al. Parkinsonism Relat Disord. 2015 Mar.

. 2015 Mar;21(3):297-9.

doi: 10.1016/j.parkreldis.2014.10.016. Epub 2014 Dec 15.

Authors

Affiliations

¹ Department of Neurology, Vanderbilt University, 1161 21st Ave South, A-0118, Nashville, TN 37232, USA. Electronic address: john.y.fang@vanderbilt.edu.
² UTHealth, The University of Texas School of Public Health, Austin Regional Campus, University of Texas Administration Building (UTA), 1616 Guadalupe Street, Suite 6.300, Austin, TX 78701, USA.
³ Department of Neurology, University of California at San Francisco, 400 Parnassus Ave, Box 0348, San Francisco, CA 94143, USA.
⁴ Department of Neurology, University of Colorado School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA.
⁵ Department of Neurology, School of Medicine, University of California at San Francisco, 505 Parnassus Ave, Box 0114, San Francisco, CA 94143-0114, USA.
⁶ Department of Neurological Sciences, University of Vermont College of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA.
⁷ Movement and Cognitive Disorders Center, Department of Neurology, Medical College of Georgia, Georgia Regents University, 1429 Harper Street, HF-1154, Augusta, GA 30912, USA.
⁸ Barrow Neurological Institute, 240 W Thomas Road, Suite 301, Phoenix, AZ 85013, USA.
⁹ Department of Neurology, University of Alabama at Birmingham and The Birmingham VA Medical Center, 1720 2nd Avenue South, Birmingham, AL 35294, USA.
¹⁰ Department of Neurology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA; Department of Ophthalmology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Brooklyn, NY 11203, USA.
¹¹ Department of Neurology, LSU Health Sciences Center in Shreveport, 1501 King's Highway, Shreveport, LA 71130, USA.
¹² Department of Neurology, Michigan State University, 804 Service Rd, Room A217, USA.

PMID: 25541182
PMCID: PMC4340731
DOI: 10.1016/j.parkreldis.2014.10.016

Abstract

Background: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected.

Objective: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD.

Methods: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life.

Results: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine.

Conclusion: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy.

Keywords: Clinical trial; Cognition; Disability; Dopamine agonist; Levodopa; Parkinson's disease.

Published by Elsevier Ltd.

PubMed Disclaimer

References

1. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al. 056 Study Group. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disorders. 2006 Nov;21(11):1844–50. - PubMed
1. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacology. 2000 Jan-Feb;23(1):34–44. - PubMed
1. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurology. 2004 Jul;61(7):1044–53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.
1. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. Published online June 11, 2014. http://dx.doi.org/10.1016/S0140-6736(14)60683-8. - DOI - PubMed
1. Elm JJ. NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disorders. 2012 Oct;27(12):1513–21. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Parkinson's disease severity and use of dopaminergic medications

Affiliations

Parkinson's disease severity and use of dopaminergic medications

Authors

Affiliations

Abstract

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials